Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SELLAS inks license deal with MSK for WT1 cancer vaccine
Initially, the deal will focus on the development of the WT1 vaccine to treat leukemia, mesothelioma, and multiple myeloma, followed by additional solid tumor indications. In order to
Initially, the deal will focus on the development of the WT1 vaccine to treat leukemia, mesothelioma, and multiple myeloma, followed by additional solid tumor indications. In order to
Ipafricept is a first-in-class fusion protein that inhibits a key signaling pathway in cancer, the Wnt pathway. The FDA removed the partial clinical hold, after the company submitted
The MAA is based on the positive results from the data collected in Japan as part of the Phase III VIBRANT trial. The trial, which met its primary
The trial is designed to assess the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of CB-5083 in multiple myeloma patients who have relapsed/refractory or refractory disease after receiving two
In the program, the company will investigate PEGPH20 (PEGylated recombinant human hyaluronidase) to show improvement in overall survival (OS). The FDA fast track status will help in the
The company said that duvelisib has shown clinical activity across a range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Currently, the safety
Apart from Sweden, ILUVIEN is currently approved for marketing in Austria, Denmark, France, Germany, Italy, Norway, Portugal, Spain and the UK, and is commercially available in the UK
In March 2000, the US Food and Drug Administration approved Zonegran as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Under the deal, Eisai
Under the deal, the two firms will work together to advance the next frontier of bi-specific antibody development platforms and bring new therapies to patients in need. CMC
Triumeq is a combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. Irrespective of racial origin, patients with